Drug Type Antibody drug conjugate (ADC) |
Synonyms LY4175408 |
Target |
Action inhibitors |
Mechanism PTK7 inhibitors(Protein-tyrosine kinase 7 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced cancer | Phase 1 | United States | 28 Jul 2025 | |
| Advanced cancer | Phase 1 | Japan | 28 Jul 2025 | |
| Advanced cancer | Phase 1 | France | 28 Jul 2025 | |
| Advanced cancer | Phase 1 | South Korea | 28 Jul 2025 | |
| Advanced cancer | Phase 1 | Spain | 28 Jul 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | United States | 28 Jul 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | Japan | 28 Jul 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | France | 28 Jul 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | South Korea | 28 Jul 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | Spain | 28 Jul 2025 |






